IBIO

iBio, Inc.

$0.78

-1.89%
SectorHealthcareIndustryBiotechnologyCountryUnited States

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space.

Source: Yahoo Finance
AI summary

Price & performance

1M-31.3%
3M-42.1%
YTD-60.2%
1Y-42.1%
52-week range—
Beta1.59
Full chart and returns against a benchmark

Q-Score

36/ 100

Quality against peers; 50 is the peer median.

Growth22
Risk35
Performance44
Valuation51
Profitability43
Leverage25
Sentiment52
Every score and metric

News sentiment

Open News

Latest results · FY 2026

Revenue$100K-75.0%
Net income-$33M
Net margin—
Historical fundamentals

Red flags in filings

1active red flag
Going-concern doubtAug 28, 2026
Filings, findings and the timeline

Revenue exposure

0%of revenue from outside the US
United States100%
Regions, segments, customers and suppliers

Valuation

IBIOIndustryP/E—89.69P/S—11.88EV/EBITDA—67.10P/B0.596.22PEG—4.02
Dividend yield0.00%
Every valuation metric